Industry & Policy News

[Artiva Biotherapeutics Inc.] AlloNK is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved natural killer cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity.

[Nature News] It is time for a redefinition of the human embryo, a team of researchers has proposed. Advances in recent years have shown that human stem cells can be used to make embryo-like structures, called embryo models, that can recreate some features of early embryo development. Such research raises ethical dilemmas because these entities don’t meet formal definitions of embryos, so are not covered by regulations governing embryo research.

[Johnson & Johnson] The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA has approved AKEEGA™ for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC.

[Brinter Bio-Implant (EurekAlert!)] Printer Bio-Implant company joined the RegeneratOR’s Innovation Accelerator in 2023, located in the Regenerative Medicine Hub, a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter, in Winston-Salem.

[Qualigen Therapeutics, Inc.] Qualigen Therapeutics, Inc. announced it is partnering with Translational Drug Development (TD2) as the contract research organization to conduct the Phase I clinical development of lead drug candidate QN-302, a small molecule G-Quadruplex-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.

[Virginia Tech] The National Institutes of Health has awarded $2.6 million to a Virginia Tech team over five years for a study of high frequency irreversible electroporation (H-FIRE) for tumor ablation and immune system activation in cases of pancreatic cancer.